Windham Venture Partners
55
32M
29
3.06
4
0.47
3
- Stages of investment
- Areas of investment
Summary
In 2006 was created Windham Venture Partners, which is appeared as VC. The company was established in North America in United States. The main office of represented VC is situated in the New York.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Neotract, CVRx, Earlens Corporation Among the most successful fund investment fields, there are SaaS, Manufacturing.
The higher amount of exits for fund were in 2019. Opposing the other organizations, this Windham Venture Partners works on 19 percentage points less the average amount of lead investments. The fund is generally included in 2-6 deals every year. The typical startup value when the investment from Windham Venture Partners is 50-100 millions dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. Considering the real fund results, this VC is 14 percentage points less often commits exit comparing to other organizations. The high activity for fund was in 2019.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Windham Venture Partners, startups are often financed by Versant Ventures, Split Rock Partners, Morgenthaler Ventures. The meaningful sponsors for the fund in investment in the same round are Vertex Ventures HC, Vertex Ventures, Versant Ventures. In the next rounds fund is usually obtained by New Enterprise Associates, Vertex Ventures HC, Versant Ventures.
The current fund was established by Adam Fine, Roger Fine. We also calculated 3 valuable employees in our database.
Investments analytics
Analytics
- Total investments
- 55
- Lead investments
- 4
- Exits
- 3
- Rounds per year
- 3.06
- Follow on index
- 0.47
- Investments by industry
- Health Care (37)
- Biotechnology (20)
- Medical (19)
- Medical Device (18)
- Health Diagnostics (13) Show 37 more
- Investments by region
-
- United States (54)
- Israel (1)
- Peak activity year
- 2019
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 60M
- Group Appearance index
- 0.93
- Avg. company exit year
- 12
- Avg. multiplicator
- 5.83
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Personal Genome Diagnostics | 04 Jan 2018 | Biotechnology, Analytics, Health Diagnostics, Genetics, Medical, Bioinformatics | Early Stage Venture | 75M | United States, Maryland, Baltimore |
Valera Health | 04 Nov 2021 | Analytics, Health Care, Hospital | Early Stage Venture | 15M | United States, New York, New York |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.